$SMTI
Sanara MedTech Inc. Stock $smti

$smti Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224031254 Filed on August 12, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$21.67M	$20.16M
YoY Change	35.24%	27.97%
Cost Of Revenue	$1.992M	$2.009M
YoY Change	13.74%	-8.18%
Gross Profit	$19.68M	$18.15M
YoY Change	37.87%	33.79%
Gross Profit Margin	90.81%	90.04%
Selling, General & Admin	$18.99M	$18.96M
YoY Change	36.86%	37.26%
% of Gross Profit	96.51%	104.45%
Research & Development	$1.360M	$985.7K
YoY Change	37.82%	-16.27%
% of Gross Profit	6.91%	5.43%
Depreciation & Amortization	$129.6K	$133.3K
YoY Change	11.15%	22.87%
% of Gross Profit	0.66%	0.73%
Operating Expenses	$21.60M	$21.03M
YoY Change	42.31%	36.31%
Operating Profit	-$1.924M	-$2.885M
YoY Change	112.21%	54.59%
Interest Expense	$927.6K	$644.3K
YoY Change	392.62%
% of Operating Profit
Other Income/Expense, Net	-$959.0K	-$644.3K
YoY Change	409.32%
Pretax Income	-$2.883M	-$3.529M
YoY Change	163.3%	89.11%
Income Tax
% Of Pretax Income
Net Earnings	-$2.858M	-$3.504M
YoY Change	169.51%	91.71%
Net Earnings / Revenue	-13.19%	-17.38%
Basic Earnings Per Share	-$0.34	-$0.41
Diluted Earnings Per Share	-$0.34	-$0.41
COMMON SHARES
Basic Shares Outstanding	8.747M shares	8.625M shares
Diluted Shares Outstanding	8.517M shares	8.469M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$16.28M	$6.150M
YoY Change	160.85%	1.49%
Cash & Equivalents	$16.28M	$6.150M
Short-Term Investments
Other Short-Term Assets	$429.4K	$489.2K
YoY Change	-30.74%	0.72%
Inventory	$3.008M	$3.565M
Prepaid Expenses
Receivables	$11.11M	$10.61M
Other Receivables	$1.079M	$0.00
Total Short-Term Assets	$31.91M	$20.81M
YoY Change	64.69%	14.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$995.8K	$1.116M
YoY Change	-24.96%	-10.0%
Goodwill	$3.602M	$3.602M
YoY Change	0.0%	0.0%
Intangibles	$42.03M	$42.98M
YoY Change	-8.62%	42.58%
Long-Term Investments	$8.321M	$3.084M
YoY Change	170.18%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$56.64M	$52.57M
YoY Change	0.96%	31.1%
TOTAL ASSETS
Total Short-Term Assets	$31.91M	$20.81M
Total Long-Term Assets	$56.64M	$52.57M
Total Assets	$88.55M	$73.38M
YoY Change	17.32%	25.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.452M	$896.0K
YoY Change	-27.4%	-19.48%
Accrued Expenses	$10.98M	$9.584M
YoY Change	9.92%	18.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.34M	$11.57M
YoY Change	8.41%	17.05%
LONG-TERM LIABILITIES
Long-Term Debt	$30.08M	$14.37M
YoY Change	217.99%
Other Long-Term Liabilities	$2.006M	$2.654M
YoY Change	-58.83%	-53.06%
Total Long-Term Liabilities	$34.75M	$20.42M
YoY Change	91.48%	174.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.34M	$11.57M
Total Long-Term Liabilities	$34.75M	$20.42M
Total Liabilities	$49.09M	$31.98M
YoY Change	56.46%	84.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$36.25M	-$33.39M
YoY Change	30.38%	24.86%
Common Stock	$76.03M	$75.09M
YoY Change	5.43%	10.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$39.78M	$41.71M
YoY Change
Total Liabilities & Shareholders Equity	$88.55M	$73.38M
YoY Change	17.32%	25.92%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$2.858M	-$3.504M
YoY Change	169.51%	91.71%
Depreciation, Depletion And Amortization	$129.6K	$133.3K
YoY Change	11.15%	22.87%
Cash From Operating Activities	$2.050M	-$1.412M
YoY Change	93.44%	-17.9%
INVESTING ACTIVITIES
Capital Expenditures	$9.100K	$58.76K
YoY Change	-94.65%	354.1%
Acquisitions
YoY Change
Other Investing Activities	-$6.348M
YoY Change	-36.14%
Cash From Investing Activities	-$6.357M	-$58.76K
YoY Change	-37.12%	354.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	14.43M	4.793M
YoY Change	56.37%	846.1%
NET CHANGE
Cash From Operating Activities	2.050M	-1.412M
Cash From Investing Activities	-6.357M	-58.76K
Cash From Financing Activities	14.43M	4.793M
Net Change In Cash	10.13M	3.322M
YoY Change	5526.01%	-370.93%
FREE CASH FLOW
Cash From Operating Activities	$2.050M	-$1.412M
Capital Expenditures	$9.100K	$58.76K
Free Cash Flow	$2.041M	-$1.471M
YoY Change	129.37%	-15.13%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18957608	usd
CY2024Q2	SMTI	Royalty Receivable RoyaltyReceivable		usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Interest Expense InterestExpense		usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	SMTI	Backend Fee BackendFee		usd
	us-gaap	Paid In Kind Interest PaidInKindInterest		usd
	SMTI	Accretion Of Finance Liabilities AccretionOfFinanceLiabilities		usd
	SMTI	Amortization And Writeoff Of Debt Issuance Costs AmortizationAndWriteoffOfDebtIssuanceCosts		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	SMTI	Cash Payment Of Deferred And Earnout Liabilities CashPaymentOfDeferredAndEarnoutLiabilities		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod		usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod		usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear		usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths		usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths		usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree		usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour		usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsWeightedAverageExercisePrice
CY2023Q2	us-gaap	Interest Expense InterestExpense		usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet		usd
CY2023Q2	SMTI	Executive Separation Costs ExecutiveSeparationCosts		usd
CY2023Q2	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts		usd
	SMTI	Executive Separation Costs ExecutiveSeparationCosts		usd
	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39678
	dei	Entity Registrant Name EntityRegistrantName	SANARA MEDTECH INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	TX
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	59-2219994
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1200 Summit Ave
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 414
	dei	Entity Address City Or Town EntityAddressCityOrTown	Fort Worth
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	76102
	dei	City Area Code CityAreaCode	(817)
	dei	Local Phone Number LocalPhoneNumber	529-2300
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	SMTI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8746976	shares
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5147216	usd
CY2023Q4	SMTI	Royalty Receivable RoyaltyReceivable	49344	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	4717533	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	489240	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	608411	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	20811428	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	19005869	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	42977404	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	44926061	usd
CY2024Q2	us-gaap	Goodwill Goodwill	3601781	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2024Q2	us-gaap	Long Term Investments LongTermInvestments	3084278	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	3084278	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1792448	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1995204	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1116266	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1257956	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	52572177	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	54865280	usd
CY2024Q2	us-gaap	Assets Assets	73383605	usd
CY2023Q4	us-gaap	Assets Assets	73871149	usd
CY2024Q2	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	6715062	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	7676770	usd
CY2024Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2475488	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2047678	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1085549	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1100000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	580357	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	393663	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	361185	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11565787	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13767877	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14371485	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9113123	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2654001	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2723001	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1512584	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1737445	usd
CY2024Q2	us-gaap	Other Long Term Debt OtherLongTermDebt	1877753	usd
CY2023Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	1941686	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	20415823	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15515255	usd
CY2024Q2	us-gaap	Liabilities Liabilities	31981610	usd
CY2023Q4	us-gaap	Liabilities Liabilities	29283132	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8746976	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8746976	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8535239	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8535239	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	8747	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8535	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	75085515	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	72860556	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33387960	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28036814	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	41706302	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	44832277	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	-304307	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-244260	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41401995	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44588017	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73383605	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73871149	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20158823	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15753164	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	2008686	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	2187516	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	18150137	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	13565648	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13811476	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	985651	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1177128	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1105507	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	803694	usd
CY2024Q2	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	13773	usd
CY2023Q2	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	360470	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	21034993	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	15431828	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2884856	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1866180	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	644346	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-644346	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-911682	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-3529202	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-1866180	usd
	us-gaap	Profit Loss ProfitLoss	-5328245	usd
	us-gaap	Profit Loss ProfitLoss	-3082509	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-25188	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-38447	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-60047	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-76876	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-3504014	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1827733	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5268198	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3005633	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.41
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8468835	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8468835	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8226271	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8226271	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8444101	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8444101	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8200173	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8200173	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41719975	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	597305	usd
CY2023Q1	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	-655942	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1033761	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-1216329	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41478770	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1127332	usd
CY2023Q2	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	224576	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-1866180	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	40964498	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	44588017	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	803386	usd
CY2024Q1	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	-580794	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-1799043	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43011566	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43011566	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1411545	usd
CY2024Q2	SMTI	Stock Issued During Period Value For Net Settlement And Retirement Of Equity Based Awards StockIssuedDuringPeriodValueForNetSettlementAndRetirementOfEquityBasedAwards	508086	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-3529202	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-3529202	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41401995	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41401995	usd
	us-gaap	Profit Loss ProfitLoss	-5328245	usd
	us-gaap	Profit Loss ProfitLoss	-3082509	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2210927	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1582569	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	155930	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	86000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	259577	usd
	us-gaap	Inventory Write Down InventoryWriteDown	69990	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2214931	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1724637	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	202756	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	144628	usd
	SMTI	Backend Fee BackendFee	52500	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	161875	usd
	SMTI	Accretion Of Finance Liabilities AccretionOfFinanceLiabilities	117267	usd
	SMTI	Amortization And Writeoff Of Debt Issuance Costs AmortizationAndWriteoffOfDebtIssuanceCosts	100883	usd
	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	79451	usd
	SMTI	Change In Fair Value Of Deferred And Earnout Liabilities ChangeInFairValueOfDeferredAndEarnoutLiabilities	813157	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2127363	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	371094	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	103012	usd
	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-77886	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-893297	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	941854	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-119172	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-618877	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1173544	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-376521	usd
	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	67682	usd
	SMTI	Increase Decrease In Accounts Payable Related Party IncreaseDecreaseInAccountsPayableRelatedParty	62620	usd
	SMTI	Increase Decrease In Royalties Payable And Expenses IncreaseDecreaseInRoyaltiesPayableAndExpenses	402610	usd
	SMTI	Increase Decrease In Royalties Payable And Expenses IncreaseDecreaseInRoyaltiesPayableAndExpenses	-248769	usd
	SMTI	Accrued Bonuses And Commissions AccruedBonusesAndCommissions	-961709	usd
	SMTI	Accrued Bonuses And Commissions AccruedBonusesAndCommissions	-1859029	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-192383	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-135436	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3006300	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3461162	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	124580	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	40650	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	650	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-124580	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-40000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	14112747	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	9750000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1033761	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-72708	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-431366	usd
	SMTI	Cash Payment Of Deferred And Earnout Liabilities CashPaymentOfDeferredAndEarnoutLiabilities	156000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4134039	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	602395	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1003159	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2898767	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5147216	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8958995	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6150375	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6060228	usd
	us-gaap	Interest Paid Net InterestPaidNet	549227	usd
	us-gaap	Interest Paid Net InterestPaidNet	6	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1369164	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_804_eus-gaap--NatureOfOperations_zTvVhibQP7Ak" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_82B_zgGXy14DXJl9">NATURE OF BUSINESS AND BACKGROUND</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara MedTech Inc. (together with its wholly owned and majority owned subsidiaries on a consolidated basis, the “Company”) is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Each of the Company’s products, services and technologies are designed to achieve the Company’s goal of providing better clinical outcomes at a lower overall cost for patients regardless of where they receive care. The Company strives to be one of the most innovative and comprehensive providers of effective surgical, wound and skincare solutions and is continually seeking to expand its offerings for patients requiring treatments across the entire continuum of care in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2020, the Company formed a subsidiary, United Wound and Skin Solutions, LLC (formerly known as “WounDerm”), to hold certain investments and operations in wound and skincare virtual consult services. In 2023, WounDerm was renamed and is now doing business as “Tissue Health Plus” (“THP”). THP is continuing its mission to simplify skin health, starting with wound care through a refined business plan. Through THP, the Company plans to offer a first of its kind value-based wound care program to payers and risk-bearing entities such as accountable care organizations and value-based care primary care companies, with Medicare Advantage payers as the initial target market for this program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As further discussed in Note 11, the Company historically managed its business on the basis of <span id="xdx_90F_eus-gaap--NumberOfOperatingSegments_dc_uInteger_c20240101__20240630_z40AUPkzX0v5" title="Number of operating segment"><span id="xdx_90A_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240101__20240630_z53KjWgzrQM4" title="Number of reportable segment">one</span></span> operating and reportable segment. During the second quarter of 2024, the Company changed its reportable segments to reflect the manner in which the business is currently managed. Based on the growing importance of the value-based wound care program to the Company’s future outlook and how the Company’s chief operating decision maker, the Chief Executive Officer, reviews operating results and makes decisions about resource allocation, the Company now has <span id="xdx_904_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20240401__20240630_zn7aQzITTyX9" title="Number of reportable segment">two</span> reportable segments: Sanara Surgical and THP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sanara Surgical </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Sanara Surgical’s soft tissue repair products include, among other products, the Company’s lead product, CellerateRX Surgical Activated Collagen (“CellerateRX Surgical”), and BIASURGE Advanced Surgical Solution, which is a no-rinse, advanced surgical solution used for wound irrigation. Sanara Surgical’s bone fusion products include, among other products, BiFORM, which is an osteoconductive, bioactive, porous implant that allows for bony ingrowth across the graft site, and ALLOCYTE Plus, which is a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanara Surgical also includes an in-house research and development team (Rochal Technologies) with an extensive pipeline of innovative products under development.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tissue Health Plus </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The THP segment is focused on value-based wound care services. Through THP, the Company plans to offer a first of its kind value-based wound care program to payers and risk-bearing entities such as accountable care organizations and value-based care (“VBC”) primary care companies, with Medicare Advantage payers as the initial target market for this program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THP’s programs are expected to enable payers to divest wound care spend risk, reduce wound related hospitalizations and improve patient quality of life. THP plans to coordinate delivery of community and home-based wound care for its managed patients. Community-based care spans a variety of settings including physician offices, skilled nursing facilities, assisted living facilities and senior living facilities. THP’s programs are intended to integrate science and evidence-based medicine protocols to standardize wound prevention and treatment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the change in reportable segments, certain prior period amounts have been recast to conform to the current period presentation. Throughout this Quarterly Report on Form 10-Q, unless otherwise indicated, amounts and activity reflect reclassifications related to the Company’s change in reportable segments. The change in reportable segments had no impact on the Company’s Consolidated Balance Sheets, Statements of Operations, Cash Flows and Shareholders’ Equity previously reported.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	integer
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	integer
CY2024Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	integer
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zdW6qxyHkX5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zlZ428dnafZa">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported revenue and expenses during the reporting period. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20158823	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15753164	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38695461	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31275081	usd
CY2024Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	90930	usd
CY2023Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	50000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	155930	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	86000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	683960	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	528030	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	4437	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3820	usd
CY2024Q2	us-gaap	Inventory Write Down InventoryWriteDown	164342	usd
CY2023Q2	us-gaap	Inventory Write Down InventoryWriteDown	39479	usd
	us-gaap	Inventory Write Down InventoryWriteDown	259577	usd
	us-gaap	Inventory Write Down InventoryWriteDown	69990	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	467508	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	446917	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2578660	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2454080	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1462394	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1196124	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1116266	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1257956	usd
CY2024Q2	us-gaap	Depreciation Depreciation	133301	usd
CY2023Q2	us-gaap	Depreciation Depreciation	108492	usd
	us-gaap	Depreciation Depreciation	266270	usd
	us-gaap	Depreciation Depreciation	216166	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3823001	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-79451	usd
	SMTI	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Revaluation Of Earnout Liability BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationRevaluationOfEarnoutLiability	-4000	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3739550	usd
CY2023Q3	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	10000000.0	usd
CY2023Q3	us-gaap	Asset Acquisition Consideration Transferred Other Assets AssetAcquisitionConsiderationTransferredOtherAssets	9750000	usd
CY2023Q3	SMTI	Asset Acquisition Consideration Transferred Equity Shares AssetAcquisitionConsiderationTransferredEquityShares	73809	shares
CY2023Q3	SMTI	Asset Acquisition Consideration Transferred Fair Value Of Stock Closing Consideration AssetAcquisitionConsiderationTransferredFairValueOfStockClosingConsideration	3089645	usd
CY2023Q3	SMTI	Asset Acquisition Consideration Transferred Fair Value Of Installment Payments AssetAcquisitionConsiderationTransferredFairValueOfInstallmentPayments	2040808	usd
CY2023Q3	SMTI	Asset Acquisition Consideration Transferred Cash Paid For Inventory AssetAcquisitionConsiderationTransferredCashPaidForInventory	30007	usd
CY2023Q3	SMTI	Asset Acquisition Consideration Transferred Fair Value Of Petito Services Defined Payments AssetAcquisitionConsiderationTransferredFairValueOfPetitoServicesDefinedPayments	825834	usd
CY2023Q3	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	893000	usd
CY2023Q3	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	162743	usd
CY2023Q3	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	16792037	usd
CY2022Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3601781	usd
CY2024Q2	us-gaap	Goodwill Goodwill	3601781	usd
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P14Y6M
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	972206	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	695202	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1944657	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1366403	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1944768	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3889537	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3872281	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3758429	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3725187	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3725187	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	22062015	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	42977404	usd
CY2024Q2	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	3084278	usd
CY2023Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	3084278	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1792448	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1906247	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	277596	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	184575	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	267223	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	175382	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	237793	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	532053	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	379529	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	297947	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	295689	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	300158	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	303892	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2347061	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	440814	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1906247	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	393663	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1512584	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y6M
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0764	pure
CY2024Q2	us-gaap	Cash Cash	3000000.0	usd
	SMTI	Annual Minimum Revenue Year One AnnualMinimumRevenueYearOne	60000000.0	usd
	SMTI	Annual Minimum Revenue Year Two AnnualMinimumRevenueYearTwo	75000000.0	usd
	SMTI	Annual Minimum Revenue Year Three AnnualMinimumRevenueYearThree	85000000.0	usd
	SMTI	Annual Minimum Revenue Year Four AnnualMinimumRevenueYearFour	95000000.0	usd
	SMTI	Annual Minimum Revenue Year Five AnnualMinimumRevenueYearFive	105000000.0	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	15214375	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9750000	usd
CY2024Q2	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	887253	usd
CY2023Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	61658	usd
CY2024Q2	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	44363	usd
CY2023Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	5138	usd
CY2024Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	842890	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	56520	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	14371485	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	9693480	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	580357	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14371485	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9113123	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	15214375	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	15214375	usd
CY2024Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	842890	usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	56520	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	100883	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	10.71
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4424	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.32
CY2022Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2031-04-22
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2023Q3	us-gaap	Cash Cash	693000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144191	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	10.71
CY2022Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4424	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.32
CY2022Q3	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	10000000.0	usd
CY2022Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	486145	shares
CY2023Q3	SMTI	Earnout Payment EarnoutPayment	693000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	1000000	shares
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	167956	shares
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	5894731	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6557465	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	144211	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	34.07
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	190240	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	35.03
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	81890	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	33.19
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	22284	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	34.53
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	230277	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	35.13
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	93892	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.22
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	62879	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.05
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	31013	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.57
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	547530.6	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	31013	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.57
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M18D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	547530.6	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16725	shares
CY2023Q4	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	10.80
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	16725	shares
CY2024Q2	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	10.80
	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2024Q2	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableNumber	16725	shares
CY2024Q2	SMTI	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	10.80
	SMTI	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M18D
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	integer
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	integer
CY2024Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	integer
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20158823	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15753164	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	18150137	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	13565648	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18957608	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13811476	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	985651	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1177128	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1105507	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	803694	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	644346	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-3529202	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-1866180	usd
CY2024Q2	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	592181	usd
CY2023Q2	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	-295624	usd
CY2024Q2	us-gaap	Assets Assets	73383605	usd
CY2023Q2	us-gaap	Assets Assets	73871149	usd
CY2024Q2	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	58762	usd
CY2023Q2	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	12945	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38695461	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31275081	usd
	us-gaap	Gross Profit GrossProfit	34796729	usd
	us-gaap	Gross Profit GrossProfit	26961906	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35149867	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26780545	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1931949	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2494452	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2210927	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1582569	usd
	us-gaap	Interest Expense InterestExpense	911682	usd
	us-gaap	Interest Expense InterestExpense	6	usd
	us-gaap	Profit Loss ProfitLoss	-5328245	usd
	us-gaap	Profit Loss ProfitLoss	-3082509	usd
	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	903602	usd
	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	-588454	usd
CY2024Q2	us-gaap	Assets Assets	73383605	usd
CY2023Q2	us-gaap	Assets Assets	73871149	usd
	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	124580	usd
	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	40650	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-3529202	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-1866180	usd
CY2024Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	644346	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1105507	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	803694	usd
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1082750	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	1127332	usd
CY2024Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-13773	usd
CY2023Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-360470	usd
CY2024Q2	SMTI	Executive Separation Costs ExecutiveSeparationCosts	904780	usd
CY2024Q2	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	397773	usd
CY2024Q2	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	592181	usd
CY2023Q2	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	-295624	usd
	us-gaap	Profit Loss ProfitLoss	-5328245	usd
	us-gaap	Profit Loss ProfitLoss	-3082509	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	911682	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	6	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2210927	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1582569	usd
	SMTI	Non Cash Share Based Compensation NonCashShareBasedCompensation	1886136	usd
	SMTI	Non Cash Share Based Compensation NonCashShareBasedCompensation	1724637	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-79451	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-813157	usd
	SMTI	Executive Separation Costs ExecutiveSeparationCosts	904780	usd
	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	397773	usd
	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	903602	usd
	SMTI	Earnings Before Interest Taxes Depreciation And Amortization EarningsBeforeInterestTaxesDepreciationAndAmortization	-588454	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	328795	usd
CY2024Q2	SMTI	Rule10b51 Arr Modified Flag Rule10b51ArrModifiedFlag	false
CY2024Q2	SMTI	Non Rule10b51 Arr Modified Flag NonRule10b51ArrModifiedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-031254-index-headers.html	Edgar Link	pending
0001493152-24-031254-index.html	Edgar Link	pending
0001493152-24-031254.txt	Edgar Link	pending
0001493152-24-031254-xbrl.zip	Edgar Link	pending
ex10-4.htm	Edgar Link	pending
ex10-6.htm	Edgar Link	pending
ex10-7.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
smti-20240630.xsd	Edgar Link	pending
smti-20240630_cal.xml	Edgar Link	unprocessable
smti-20240630_def.xml	Edgar Link	unprocessable
smti-20240630_lab.xml	Edgar Link	unprocessable
smti-20240630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SMTI
Sanara MedTech Inc. Stock $smti

2024 Q3 Form 10-Q Financial Statement

#000149315224031254 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI Sanara MedTech Inc. Stock $smti

2024 Q3 Form 10-Q Financial Statement

#000149315224031254 Filed on August 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SMTI
Sanara MedTech Inc. Stock $smti